var data={"title":"Diatrizoate meglumine and diatrizoate sodium (Gastrografin): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Diatrizoate meglumine and diatrizoate sodium (Gastrografin): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6011?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=diatrizoate-meglumine-and-diatrizoate-sodium-gastrografin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Diatrizoate meglumine and diatrizoate sodium (Gastrografin): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10498764\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate use (injection only):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Not for intrathecal use.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158959\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Gastrografin;</li>\n      <li>MD-76 R [DSC];</li>\n      <li>MD-Gastroview</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50692539\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Gastrografin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158961\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Iodinated Contrast Media;</li>\n      <li>\n        Radiological/Contrast Media (Ionic, High Osmolality)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1751178\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Aortography:</b> IV or intra-arterial: 15 to 40 mL as a single injection; may repeat if needed. Maximum dose: 160 mL. Consult product labeling for additional procedure specific warnings/precautions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Contrast enhancement in body computed tomography (CT):</b> IV (rapid infusion and/or bolus injection): 25 to 50 mL; may repeat as necessary. A rapid infusion of a 100 mL dose may be used when prolonged enhancement is required. Consult product labeling for additional procedure specific warnings/precautions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Contrast enhancement of CT brain imaging (tumors or non-neoplastic conditions):</b> IV: 1.3 mL/kg; maximum: 125 mL. Adequately hydrate patient prior to procedure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Digital subtraction angiography:</b> IV (central or peripheral injection): 20 to 60 mL; may repeat as necessary. Adequately hydrate patient prior to procedure. Consult product labeling for additional procedure specific warnings/precautions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Excretory urography:</b> IV: Usual dose: 20 mL; may administer a 40 mL dose if inadequate visualization occurs or poor visualization is anticipated. <b>Note:</b> Ensure low residue diet the day prior to procedure with a laxative given the evening prior to the procedure unless contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peripheral arteriography:</b> Intra-arterial (femoral or subclavian artery): Consult product labeling for additional procedure specific warnings/precautions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Visualization of entire extremity: 20 to 40 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Visualization for lower or upper half of extremity: 10 to 20 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Radiographic exam of GI tract segments:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 30 to 90 mL; decrease dose in debilitated or dehydrated patients</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rectal enema/enterostomy instillation: Dilute 240 mL in 1000 mL tap water</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Selective coronary arteriography (with or without left ventriculography):</b> Intra-arterial (into either coronary artery): Usual dose 4 to 10 mL; may repeat as necessary. Total doses up to 150 mL have been given. Consult product labeling for additional procedure specific warnings/precautions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Left ventriculography:</b> Usual dose 35 to 50 mL; may repeat as necessary. Maximum total dose for combined selective coronary arteriography with left ventriculography: 200 mL. Consult product labeling for additional procedure specific warnings/precautions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Selective renal arteriography:</b> Intra-arterial (via femoral artery catheterization): Usual dose: 5 to 10mL; may repeat as necessary.  Total doses up to 60 mL have been given.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Selective visceral arteriography:</b> Intra-arterial: Usual doses (may repeat as necessary):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Superior mesenteric artery: 40 mL (range: 30 to 60 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Inferior mesenteric artery: 15 mL (range: 10 to 25 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Celiac artery: 40 mL (range: 30 to 50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic artery: 25 mL (range: 15 to 35 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Splenic artery: 35 mL (range: 30 to 40 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tomography:</b> Oral: Dilute 25 to 77 mL in 1000 mL tap water, then administer 240 mL of this solution 15 to 30 minutes prior to imaging</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Adhesive small intestine obstruction treatment (off-label):</b> Oral/nasogastric tube: Adults: Up to 150 mL\t; some studies suggest dilution prior to administration (Branco 2011, Di Saverio 2008)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1751177\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Angiocardiography:</b> IV (injected into larger peripheral vein or by direct catheterization of the heart):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &lt;5 years: 10 to 20 mL. <b>Note:</b> The risk of using this dose in children weighing &lt;7 kg is increased especially if infants have pre-existing right heart strain, right heart failure, or decreased or obliterated pulmonary vascular beds.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 5 to 10 years: 20 to 30 mL; up to 100 mL have been administered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Aortography:</b> IV or intra-arterial: Adolescents &gt;16 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Excretory urography:</b> IV: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;6 months: 4 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">6 to 12 months: 6 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1 to 2 years: 8 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">2 to 5 years: 10 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">5 to 7 years: 12 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">8 to 10 years: 14 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">11 to 15 years: 16 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;16 years: Refer to adult dosing</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Ensure low residue diet the day prior to procedure with a laxative given the evening prior to the procedure unless contraindicated. Do not fluid restrict infants and young children prior to procedure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peripheral arteriography:</b> Intra-arterial (femoral or subclavian artery): Children and Adolescents: Adjust adult dose proportionally based on body weight. Consult product labeling for additional procedure specific warnings/precautions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Radiographic exam of GI tract segments:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;5 years: 30 mL; may dilute 1:1 in a recommended liquid (if patient &lt;10 kg or debilitated, should dilute 1:3 in water)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 5 to 10 years: 60 mL; may dilute 1:1 in a recommended liquid (if patient &lt;10 kg or debilitated, should dilute 1:3 in water)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;10 years and Adolescents: Dosage varies.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rectal enema/enterostomy instillation:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;5 years: Dosage varies. Dilute 1:5 in tap water</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;5 years: Dilute 90 mL in 500 mL tap water</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1751179\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Radiographic exam of GI tract segments:</b> Oral: 30 to 90 mL; If patient is cachectic, a 1:1 dilution of the oral solution using a recommended liquid is recommended. Decrease dose in debilitated or dehydrated patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Other indications:</b> Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15670061\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer's labeling. Use caution in severe impairment and in setting of combined renal and hepatic disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15670062\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer's labeling. Use caution in patients with combined hepatic and renal disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158951\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution, injection:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">MD-76 R: Diatrizoate meglumine 660 mg and diatrizoate sodium 100 mg per 1 mL (50 mL, 100 mL, 200 mL) [provides organically-bound iodine 370 mg/mL; contains edetate calcium disodium, sodium 3.65 mg (0.16 mEq)/mL] [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution, oral/rectal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrografin: Diatrizoate meglumine 660 mg and diatrizoate sodium 100 mg per 1 mL (30 mL, 120 mL) [provides organically-bound iodine 367 mg/mL; contains edetate disodium, sodium 4.8 mg (0.21 mEq)/mL; lemon flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">MD-Gastroview: Diatrizoate meglumine 660 mg and diatrizoate sodium 100 mg per 1 mL (30 mL, 120 mL, 240 mL) [provides organically-bound iodine 367 mg/mL; contains edetate disodium, sodium 4.8 mg (0.21 mEq)/mL; lemon-vanilla flavor]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158948\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1751180\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: May be administered diluted. May be diluted 1:1 with water, carbonated beverage, milk, or mineral oil for infants, children, and cachectic elderly; for very young (less than 10 kg) and debilitated children, must dilute 1:3 in water. May administer in a bottle to infants. Maintain an open IV fluid line in pediatric or severely debilitated patients in case hypotension or shock occurs and rehydration is required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rectal: Administer diluted prior to enema or enterostomy instillation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection (intra-arterial, IV): Administer at body temperature; may need to be warmed before use. Slow or stop the injection if a minor reaction occurs during administration; discontinue if a major reaction occurs. Patient should omit the meal that precedes the examination. Appropriate premedication (eg, barbiturate, tranquilizer or an analgesic) may be administered prior to the examination. Patients with a strong allergic history may receive an antihistamine within 30 minutes of administration of the contrast agent and corticosteroids prior to and for 24 hours after the contrast agent.  Procedure specific administration considerations should also be reviewed; see product labeling for details. When using for IV digital subtraction angiography and administering via a central catheter using a power injector, administer at a rate of 10 to 30 mL/second. With peripheral injection, administer at a rate of 12 to 20 mL/second (depending on size of vein); flush vein immediately following injection with 20 to 25 mL of D<sub>5</sub>W or NS. </p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do NOT flush the line); remove needle/cannula; initiate hyaluronidase antidote; elevate extremity.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Hyaluronidase:</i> Intradermal or SubQ: Inject a total of 1 mL (15 units/mL) as five separate 0.2 mL injections (using a 25-gauge needle) into area of extravasation at the leading edge in a clockwise manner (MacCara, 1983; Zenk, 1981) or injection of a total of 5 mL (150 units/mL) as five separate 1 mL injections around the extravasation site has been also used successfully (Rowlett, 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158952\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral/rectal: Radiographic examination of GI tract; adjunct to contrast enhancement in computed tomography of the torso (in conjunction with an IV radiopaque contrast agent)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection: Angiocardiography (pediatric), aortography, contrast enhancement of brain or body computed tomographic (CT), digital subtraction angiography, excretory urography, peripheral arteriography, selective coronary arteriography (with or without left ventriculography), selective renal arteriography, selective visceral arteriography</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475028\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Adhesive small intestine obstruction (ASIO)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5978075\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1751166\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined. Some reactions listed are based on reports for other agents in this same pharmacologic class, and may not be specifically reported for diatrizoate meglumine and diatrizoate sodium. Specific procedure-related adverse events may also occur with the injectable route of administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Oral/rectal:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Tachyarrhythmia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Erythema, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea, hypoxia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Injection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Arterial thrombosis at injection site (with peripheral arteriography), brachial plexopathy (palsy following axillary artery injections [with peripheral arteriography]), cardiac arrhythmia (with pediatric angiocardiography, aortography, or coronary arteriography), cardiovascular signs and symptoms (severe including cardiac arrest; with excretion urography), chest pain (with coronary arteriography), choking sensation, ECG changes (transient, with coronary angiography), edema, flushing, hypertension, hypotension, myocardial infarction (with coronary arteriography), partial collapse of the injected vein, peripheral vasodilation, venospasm (injection site), venous pain (injection site), ventricular fibrillation (with excretion urography or coronary angiography)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Chills, dizziness, feeling hot, headache</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Acute generalized exanthematous pustulosis, diaphoresis, erythema, pallor, pruritus, skin discoloration, skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypothyroidism, altered thyroid hormone levels (transient suppression)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea, retching, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Nephrotoxicity (with aortography, including renal infarction, acute tubular necrosis with oliguria and anuria)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; Oncologic: Disseminated intravascular coagulation, facial petechiae, neutropenia, retroperitoneal hemorrhage (with aortography, translumbar approach)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylactoid reaction, anaphylaxis (with severe asthmatic reaction [with excretion urography]), hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: DRESS syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Bleeding at injection site (with peripheral arteriography), burning sensation at injection site, injection site numbness, pain at injection site, inflammation at injection site, tissue necrosis at injection site (with extravasation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Muscle cramps, spinal cord injury (with aortography), tremors, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Conjunctival petechiae, lacrimation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Acute renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Sneezing, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever, procedural complications (injury to aorta and neighboring organs [with aortography]; hemorrhage, thrombosis, pseudoaneurysms at the puncture site, dislodgment of arteriosclerotic plaques [with coronary arteriography])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Thyroid dysfunction (underactive; premature infants and infants with underlying medicals conditions are more vulnerable)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158954\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Hypersensitivity to diatrizoate or any component of the formulation; use in myelography (injection only)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1751163\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aspiration: Aspiration may occur following oral administration; serious complications may result due to the formation of a copious osmotic effusion. Avoid use in patients with esophagotracheal fistula; ensure proper positioning of the tube in the stomach prior to administration via nasogastric tube.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contrast media reactions: Adverse reactions (including delayed reactions) to iodine-containing contrast media have occurred. Most cases are minor; however, serious and life-threatening reactions may occur without warning and often resemble allergic-type reactions. Patients with a history of bronchial asthma, allergy (including food allergy), family history of allergy, or prior allergy or hypersensitivity to contrast agents are at a higher risk for allergic reaction. Obtain allergy and hypersensitivity history prior to administration. Pretesting for allergic reaction may not reliably predict potential for reaction. Premedication with antihistamines and corticosteroids should be considered in patients at risk for allergic reaction (strong allergy history, prior contrast media reaction, or positive pretest) to reduce the incidence and severity of reactions. Begin corticosteroids early prior to contrast media and continue for 24 hours after administration. Administer antihistamines within 30 minutes before contrast agent. Monitor closely for 30 to 60 minutes after administration of the contrast media and discontinue immediately if a serious reaction occurs. For minor reactions, the infusion may be slowed or interrupted until the reaction subsides. A higher incidence of adverse reactions was reported in patients also receiving general anesthesia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatological effects: Severe cutaneous adverse reactions (including Stevens-Johnson syndrome [SJS], toxic epidermal necrolysis [TEN], acute generalized exanthematous pustulosis [AGEP], drug reaction with eosinophilia and systemic symptoms [DRESS]) have occurred 1 hour to several weeks after administration; reaction severity may increase and time to onset may decrease with repeat administration. Avoid use in patients with a history of a severe cutaneous adverse reaction to diatrizoate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dehydration: Use of hypertonic oral/rectal contrast solutions may cause hypovolemia and hypotension due to fluid loss from the intestines. Specific dilution guidelines are provided for administering solutions to young children, children &lt;10 kg, the elderly, or dehydrated and/or debilitated persons. Correct electrolyte imbalances prior to administration of hypertonic contrast solutions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Vesicant; ensure proper needle/catheter/line placement prior to and during administration. Avoid infiltration. May cause thrombophlebitis; tissue necrosis may occur with extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypothyroidism: Thyroid function tests indicative of hypothyroidism or transient thyroid suppression have been reported (uncommon) in adult and pediatric patients (including infants); some patients were treated for hypothyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity: Serious neurologic sequelae, including permanent paralysis have occurred following injection of concentrated contrast media into arteries supplying the spinal cord. During aortography by the translumbar technique, use extreme caution to avoid inadvertent intrathecal injection. Do not inject contrast media after administration of vasopressors; may potentiate neurologic effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal failure: Renal failure has been reported in patients with hepatic impairment administered an oral cholecystographic agent followed by an intravascular iodinated radiocontrast agent. Avoid fluid restriction and maintain normal hydration in patients with diabetes, diabetic nephropathy, susceptible patients without diabetes (eg, elderly patients with preexisting renal disease), and patients with occult renal disease (particularly patients with diabetes and/or hypertension). Preparatory dehydration may contribute to acute renal failure in infants, young children, elderly patients, and patients with preexisting renal impairment, multiple myeloma, advanced vascular disease, and diabetes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolic events: Serious, rarely fatal, thromboembolic events causing myocardial infarction (MI) and stroke have been reported with intravascular administration during angiographic procedures with both ionic and nonionic contrast media. Ionic iodinated contrast media may inhibit blood coagulation (more than nonionic contrast media). Use meticulous intravascular administration techniques especially during angiographic procedures. Clotting has been reported when in vitro blood remains in contact with syringes containing nonionic contrast media; use of plastic syringes in place of glass syringes has been reported to decrease, but not eliminate, the likelihood of in vitro clotting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Preparatory dehydration may contribute to acute renal failure in patients with advanced vascular disease; avoid fluid restriction and maintain normal hydration in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cerebral lesions: Seizures have occurred in patients with cerebral lesions (primary or metastatic) following administration of contrast agent for CT brain images.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Preparatory dehydration may contribute to acute renal failure in patients with diabetes; avoid fluid restriction and maintain normal hydration in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Endotoxemia: Injection: Use with caution in patients with endotoxemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fever: Injection: Use with caution in patients with elevated body temperature.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with combined renal and hepatic disease; excretion may be impaired.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Homocystinuria: Avoid angiography in patients with homocystinuria; may be at risk for thrombosis and embolism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperacidity: Conditions that promote GI hyperacidity (eg, fasting, emotional upset, stress) may lead to the precipitation of orally administered water-soluble contrast agents; potential for false interpretation of precipitate as a GI anatomical abnormality or injury should be kept in mind.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthyroidism: Thyroid storm following intravascular administration of iodinated contrast media has occurred in patients with hyperthyroidism or with an autonomously functioning thyroid nodule. Use with caution in patients who are hyperthyroid or euthyroid with a goiter.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple myeloma: Use with caution in patients with multiple myeloma; use of intravascular contrast agents may cause anuria, progressive uremia, and renal failure (potentially fatal). Partial dehydration in preparation for the procedure is not recommended in these patients since it may contribute to precipitation of the myeloma protein in the renal tubules.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pheochromocytoma: Use with extreme caution in patients with pheochromocytoma (known or suspected); use the minimum amount of intravascular contrast agent and monitor blood pressure closely throughout the procedure. Therapy to manage hypertensive crisis should be readily available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Injection: Use caution in patients with advanced renal disease; excretion may be impaired. Risk may be increased with concomitant hepatic impairment, heart failure, severe hypertension or recent renal transplant. Preparatory dehydration may contribute to acute renal failure in patients with preexisting renal impairment. Iodinated contrast agents may cause acute renal failure in patients with diabetic nephropathy or susceptible nondiabetic patients (eg, elderly with preexisting renal disease).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sickle cell disease: Use with caution in sickle cell disease; intravenous or intra-arterial administration may promote sickling in patients homozygous for sickle cell disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Subarachnoid hemorrhage: Injection: Use with caution in patients with subarachnoid hemorrhage; contrast media administration may be associated with rare clinical deterioration (including seizure and fatality).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Debilitated patients: Use oral/rectal hypertonic contrast agents with caution in debilitated patients due to the potential for fluid loss from the intestine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly. Acute renal failure may occur following intravascular administration of iodinated contrast agents in elderly with pre-existing renal impairment. Hypovolemia, hypotension, and shock may occur in elderly cachectic patients following oral/rectal administration of the hypertonic contrast agent solution if dilution instructions are not followed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Use with caution in children. Injury to the colonic mucosa may occur if oral/rectal dilution instructions are not followed; risk may be increased with underlying diseases which affect intestinal viability. Hypovolemia, hypotension, and shock may occur in young debilitated children following oral/rectal administration of the hypertonic contrast agent solution if dilution instructions are not followed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aortography: Hazards of aortography include those associated with the particular technique used, the contrast medium and the underlying pathology warranting the procedure. Carefully evaluate the position of the catheter tip or needle to prevent inadvertent injection of a large dose into a branch of the aorta (eg, brachiocephalic vessels, renal arteries) or intramurally.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <b>[US Boxed Warning]: Injectable solution is not for intrathecal administration.</b> Serious adverse events (including death, seizure, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, and brain edema) have been reported following inadvertent intrathecal injection. Avoid inadvertent administration to the subarachnoid space. In contrast-enhanced computerized tomography (CECT), contrast may obscure some lesions previously seen on unenhanced CT scans.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Rectal administration: Undiluted solutions may cause mucosal irritation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Trained personnel: Clinicians using radiopaque contrast agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use during and for 30 to 60 minutes after administration (delayed reactions have occurred).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299176\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6219796\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8542&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158949\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158956\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Following IV administration, diatrizoate salts cross the placenta and may enter fetal circulation. In general, use of iodinated contrast media agents should be avoided unless absolutely required to obtain diagnostic information that will influence the care of the mother or fetus during pregnancy (ACOG 2016; ACR 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158957\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Diatrizoate salts are reported to be present in human milk. The manufacturer recommends bottle feedings for 24 hours following administration of the injection and to use caution following use of the oral/rectal preparations. Because of the low expected excretion of iodinated contrast agents into breast milk and the low absorption from an infant&rsquo;s GI tract, other sources note breast-feeding may be continued without interruption (ACOG 2016; ACR 2015). Theoretically, the taste of milk could be altered if it contains contrast media. Women who prefer to temporarily withhold breast-feeding can pump and store milk prior to the procedure and abstain from breast-feeding for 12 to 24 hours (ACR 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9730005\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15670086\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor blood pressure, hydration, serum osmolarity, electrolyte status; monitor for extravasation during intravenous administration; renal function (especially in patients receiving large intravascular doses). Following intravascular administration, monitor for delayed, severe adverse reactions for &ge;30 to 60 minutes. Procedure specific monitoring considerations should also be reviewed; see product labeling for details.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26998844\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Radiopaque contrast agent; opacifies vessels or tissues in the path of the flow of the contrast medium, permitting radiographic visualization of the internal structures of the body.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15669974\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Sparingly absorbed following oral administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Poorly bound to albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Injection: Initial: 10 minutes; Terminal: 100 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Injection: Urine (patients with healthy renal function); liver and small intestine (patients with severe renal impairment)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323106\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Gastrografin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">66-10% (30 mL): $29.01</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (MD-Gastroview Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">66-10% (30 mL): $19.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038598\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Gastrografin (AU, CL, CY, EG, ES, FI, GR, KR, KW, MT, NO, NZ, QA, SA);</li>\n      <li>Gastrografine (FR);</li>\n      <li>MD 76 (AU);</li>\n      <li>MD Gastroview (AU, NZ, SG);</li>\n      <li>MD-76R (AR);</li>\n      <li>MD-Gastroview (LK);</li>\n      <li>Pielograf (CO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee Opinion No. 656: guidelines for diagnostic imaging during pregnancy and lactation. <i>Obstet Gynecol</i>. 2016;127(2):e75-e80. doi:10.1097/AOG.0000000000001316.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diatrizoate-meglumine-and-diatrizoate-sodium-gastrografin-drug-information/abstract-text/26942391/pubmed\" target=\"_blank\" id=\"26942391\">26942391</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Radiology Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. Version 10.1. http://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast%20Manual/2015_Contrast_Media.pdf. Published 2015. Accessed April 15, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20205228\"></a>Branco BC, Barmparas G, Schn&uuml;riger B, et al. Systematic review and meta-analysis of the diagnostic and therapeutic role of water-soluble contrast agent in adhesive small bowel obstruction. <i>Br J Surg</i>. 2010;97:470-478.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diatrizoate-meglumine-and-diatrizoate-sodium-gastrografin-drug-information/abstract-text/20205228/pubmed\" target=\"_blank\" id=\"20205228\">20205228</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18688562\"></a>Di Saverio S, Catena F, Ansaloni L, et al, &ldquo;Water-soluble Contrast Medium (Gastrografin) Value in Adhesive Small Intestine Obstruction (ASIO): A Prospective, Randomized, Controlled, Clinical Trial,&rdquo; <i>World J Surg</i>, 2008, 32(10):2293-304.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diatrizoate-meglumine-and-diatrizoate-sodium-gastrografin-drug-information/abstract-text/18688562/pubmed\" target=\"_blank\" id=\"18688562\">18688562</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    FDA Safety Alert. MedWatch. Iodine-containing contrast agents for medical imaging. Food and Drug Administration website. <a href=\"http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm472995.htm\" target=\"_blank\">http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm472995.htm</a>. Updated November 17, 2015. Accessed November 18, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gastrografin (diatrizoate meglumine and diatrizoate sodium) [prescribing information]. Princeton, NJ: Bracco Diagnostics Inc; December 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gastrografin (diatrizoate meglumine and diatrizoate sodium) [product monograph]. Montreal, Quebec, Canada: Bracco Imagining Canada; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jneid H, Anderson JL, Wright RS, et al, &ldquo;2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo; <i>Circulation</i>, 2012, 126(7):875-910.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diatrizoate-meglumine-and-diatrizoate-sodium-gastrografin-drug-information/abstract-text/22800849/pubmed\" target=\"_blank\" id=\"22800849\">22800849</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klein LW, Sheldon MW, Brinker J, et al, &ldquo;The Use of Radiographic Contrast Media During PCI: A Focused Review: A Position Statement of the Society of Cardiovascular Angiography and Interventions,&rdquo; <i>Catheter Cardiovasc Interv</i>, 2009, 74(4):728-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diatrizoate-meglumine-and-diatrizoate-sodium-gastrografin-drug-information/abstract-text/19830793/pubmed\" target=\"_blank\" id=\"19830793\">19830793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Laskey WK, Jenkins C, Selzer F, et al, &ldquo;Volume-to-Creatinine Clearance Ratio: A Pharmacokinetically Based Risk Factor for Prediction of Early Creatinine Increase After Percutaneous Coronary Intervention,&rdquo; <i>J Am Coll Cardiol</i>, 2007, 50(7):584-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diatrizoate-meglumine-and-diatrizoate-sodium-gastrografin-drug-information/abstract-text/17692741/pubmed\" target=\"_blank\" id=\"17692741\">17692741</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo; <i>Circulation</i>, 2011, 124(23):e574-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diatrizoate-meglumine-and-diatrizoate-sodium-gastrografin-drug-information/abstract-text/22064601/pubmed\" target=\"_blank\" id=\"22064601\">22064601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacCara ME. Extravasation: a hazard of intravenous therapy. <i>Drug Intell Clin Pharm</i>. 1983;17(10):713-717.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diatrizoate-meglumine-and-diatrizoate-sodium-gastrografin-drug-information/abstract-text/6628223/pubmed\" target=\"_blank\" id=\"6628223\">6628223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MD-76R (diatrizoate meglumine and diatrizoate sodium injection) [prescribing information]. St. Louis, MO: Mallinckrodt; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MD-Gastroview (diatrizoate meglumine and diatrizoate sodium) [prescribing information]. St. Louis, MO: Mallinckrodt Inc; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rowlett J. Extravasation of contrast media managed with recombinant human hyaluronidase. <i>Am J Emerg Med</i>. 2012;30(9):2102.e1-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diatrizoate-meglumine-and-diatrizoate-sodium-gastrografin-drug-information/abstract-text/22633726/pubmed\" target=\"_blank\" id=\"22633726\">22633726</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zenk KE. Management of intravenous extravasations. <i>Infusion</i>. 1981;5(4):77-79.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8542 Version 111.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F10498764\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F158959\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50692539\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F158961\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F1751178\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F1751177\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F1751179\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15670061\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15670062\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F158951\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F158948\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1751180\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F158952\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475028\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5978075\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F1751166\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F158954\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F1751163\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299176\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6219796\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F158949\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F158956\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F158957\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F9730005\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F15670086\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F26998844\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F15669974\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323106\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038598\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8542|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=diatrizoate-meglumine-and-diatrizoate-sodium-gastrografin-patient-drug-information\" class=\"drug drug_patient\">Diatrizoate meglumine and diatrizoate sodium (Gastrografin): Patient drug information</a></li></ul></div></div>","javascript":null}